Rockwell Medical Stock News

WIXOM, Mich., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

AQR Capital Management LLC trimmed its position in Rockwell Medical, Inc. (NASDAQ:RMTI) by 88.6% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 83,668 shares of the companys stock after selling 647,163 shares during the period. AQR Capital Management LLCs holdings in Rockwell Medical were worth $76,000 []

Geode Capital Management LLC reduced its stake in Rockwell Medical, Inc. (NASDAQ:RMTI) by 42.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 711,373 shares of the companys stock after selling 533,117 shares during the quarter. Geode Capital Management LLC owned 0.76% of []

Rockwell Medical, Inc. (RMTI) with the stream of -3.13% also noticed, India ECMOHO Limited (MOHO) encountered a rapid change of 3.44% in the last hour of Fridays trading session. Rockwell The post Remarkable Stock in Review: Rockwell Medical, Inc. (NASDAQ:RMTI), ECMOHO Limited (NASDAQ:MOHO) appeared first on Stocks Equity .

Rockwell Medical (NASDAQ:RMTI) issued its quarterly earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.07) by ($0.01), MarketWatch Earnings reports. Rockwell Medical had a negative return on equity of 106.66% and a negative net margin of 52.69%. During the same quarter in the []

Toward the end of trading Wednesday, the Dow traded down 0.58% to 35,930.89 while the NASDAQ fell 0.27% to 15,930.79. The SP also fell, dropping 0.23% to 4,690.24. The U.S. has the highest number of

Rockwell Medical Inc (NASDAQ: RMTI) has announced the publication of results in the Journal of Bioequivalence & Bioavailability from a study evaluating the co-administration of intravenous (IV) Fer

The shares of Rockwell Medical Inc (NASDAQ: RMTI) increased by over 55% pre-market today. This is why it happened.

Findings confirm results from previous population PK study demonstrating safe and effective anticoagulation along with the delivery of Ferric Pyrophosphate Citrate iron Findings confirm results from previous population PK study demonstrating safe and effective anticoagulation along with the delivery of Ferric Pyrophosphate Citrate iron

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q3 2021 Results - Earnings Call Transcript

- Third quarter net sales of $16.0 Million , up 6% sequential quarter-over-quarter and 5% year-over-year - - Company recently submitted Investigational New Drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -14.29% and -11.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical (NASDAQ:RMTI) reported its Q3 earnings results on Monday, November 15, 2021 at 04:00 PM. Here's what investors need to know about the announcement.